Literature DB >> 3046443

[The production of hybrid cells producing monoclonal antibodies against Toxoplasma gondii].

W A Müller1, K Becker, A Schäfer, G Koch, H L Borkhardt.   

Abstract

Hybridomas that secrete monoclonal antibody to Toxoplasma gondii have been developed. Two groups of 10 female BALB/c mice each were immunized either over a shorter (71 d) or longer (117 d) period at first with Toxoplasma lysate antigen and afterwards with intact tachyzoites of the RH strain. Higher titres of antibody were obtained with the long-period immunization. The fusion experiments have shown that both schemes of immunization approximately result in the same number (16 and 14% respectively) of hybridoma cell lines producing antigen-specific monoclonal antibodies. Hybridoma cultures secreting antitoxoplasma monoclonal antibodies were screened parallel by indirect immunofluorescence antibody test (IFAT) and enzyme immunoassay (EIA). 16 of the hybridoma cell cultures produced positive results only in the IFAT, 112 reacted only in the EIA and 21 were positive in both tests. The monoclonal antibodies 5B10, 5G6 and 1B2, which are positive in the IFAT form a chemical compound with the major antigens on the surface of RH tachyzoites. The patterns of fluorescence produced by these monoclonal antibodies are in conformity with those produced by using polyclonal sera of Toxoplasma gondii infected hosts (mouse, rabbit, man).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3046443

Source DB:  PubMed          Journal:  Angew Parasitol        ISSN: 0003-3162


  3 in total

1.  Identification of a virulence-associated antigen of Toxoplasma gondii by use of a mouse monoclonal antibody.

Authors:  U Gross; W A Müller; S Knapp; J Heesemann
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

2.  An identical epitope in Pneumocystis carinii and Toxoplasma gondii causing serological cross reactions.

Authors:  A Hassl; W A Müller; H Aspöck
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

3.  Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity.

Authors:  Robin A Nadar; Kambiz Farbod; Karlijn Codee-van der Schilden; Lukas Schlatt; Barbara Crone; Nandini Asokan; Alessandra Curci; Michael Brand; Martin Bornhaeuser; Michele Iafisco; Nicola Margiotta; Uwe Karst; Sandra Heskamp; Otto C Boerman; Jeroen J J P van den Beucken; Sander C G Leeuwenburgh
Journal:  Sci Rep       Date:  2020-04-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.